FDA OKs expanded use for Amgen’s Nplate

The FDA approves Amgen’s (NASDAQ:AMGN) Nplate (romiplostim) for use in newly diagnosed adults with immune thrombocytopenia (ITP) (low blood platelets) who have not responded adequately to corticosteroids, immunoglobulins or splenectomy (spleen removal).

The agency approved the thrombopoietin receptor agonist in August 2008 for the long-term treatment of adults with chronic ITP and in December 2018 for pediatric ITP patients.

https://seekingalpha.com/news/3506910-fda-oks-expanded-use-amgens-nplate